A Phase 2 interventional study of Lenvatinib (DTC Cohort) and Lenvatinib (MTC Cohort) in Thyroid Cancer, sponsored by Eisai Inc.. Completed at 42 sites in 6 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-04-22.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing lenvatinib in Thyroid Neoplasms — 6 open to participants now, 7 under way, none of them phase 3. lenvatinib · Thyroid Neoplasms.
Among the 17 studies testing lenvatinib in Thyroid Neoplasms, this one is the 6th largest by enrollment, is the only one that started in 2008, is one of 10 in phase 2, and was the 1st registered.
785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.
Browse Thyroid Neoplasms studies →6 of the 17 studies testing lenvatinib in Thyroid Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 18+
Fudan University · Sites in China
Fujian Medical University · Sites in China
Ages 18–80
Zhejiang University · Sites in China
Ages 18+
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
17 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 54 across 520 interventional studies indexed under Thyroid Neoplasms.
Median enrollment 35 across the 17 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
10 studies in Thyroid Neoplasms by Eisai Co., Ltd.: none open now, none under way, none of them phase 3. Of 8 finished, 4 (50%) have results posted.
Among the 10 studies in Thyroid Neoplasms by Eisai Co., Ltd., this one is the only one that started in 2008, is one of 4 in phase 2, and was the 2nd registered.
Eisai Co., Ltd.’s Thyroid Neoplasms studies by the year they started, since 2005.
3 of the studies testing lenvatinib in Thyroid Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06195228Fudan UniversityA Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer | 2026-12-31 |
| NCT06848920Zhejiang UniversityStudy of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma | 2027-06-30 |
| NCT04171622M.D. Anderson Cancer CenterLenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing lenvatinib in Thyroid Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 10 in Thyroid Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and efficacy of oral lenvatinib in participants with medullary thyroid cancer (MTC) or radioiodine (131 I)-refractory/resistant differentiated thyroid cancer (DTC), unresectable differentiated thyroid cancers, stratified by Histology.
This study contained 3 Phases: the Pretreatment Phase, the Treatment Phase, and the Extension Phase. The Pretreatment Phase lasted no longer than 28 days. Informed consent was obtained and protocol eligibility and disease characteristics were established prior to treatment. The Treatment Phase consisted of a Treatment Period and a Follow-up Period. The Treatment Period of the Treatment Phase began at the time that the first participant began study drug administration and ended at the time when all participants enrolled completed 8 cycles of treatment or discontinued study treatment prior to the eighth cycle (ie, time of data cutoff for the primary study analysis [Primary Completion Date]). All participants then entered the Extension Phase. The Extension Phase consisted of a Treatment Period and a Follow-up Period. The Extension Phase began immediately after the Treatment Phase ended and included all participants that were either still receiving treatment or in follow-up. The time of data cutoff for the primary study analysis occurred when all subjects in the study completed 8 cycles of treatment or discontinued study treatment prior to the eighth cycle.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
meeting the following criterion:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm will enroll participants with radioiodine (131 I)-refractory/resistant differentiated thyroid cancer.
Drug: Lenvatinib (DTC Cohort)
This arm will enroll participants with medullary thyroid cancer.
Drug: Lenvatinib (MTC Cohort)
24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily, or 10 mg lenvatinib orally twice daily (20 mg total). Out of 58 participants in the DTC cohort, 56 participants received 24 mg lenvatinib once daily and 2 participants received 10 mg lenvatinib twice daily (total 20 mg daily), given continuously in 28-day treatment cycles.
Also known as: E7080, LENVIMA
24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily given continuously in 28-day treatment cycles.
Also known as: E7080, LENVIMA
Objective Response Rate (ORR)
ORR was the percentage of participants with best overall response (BOR) of complete response (CR) and partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 for target lesions using magnetic resonance imaging/computed tomography (MRI/CT) scans, as determined by independent imaging review (IIR). CR was defined as disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter. ORR=CR+PR, was presented with 2-sided 95% confidence interval (CI) by the method of Clopper and Pearson.
Time frame: From date of treatment start until disease progression, development of unacceptable toxicity, withdrawal of consent, participant's choice to stop study treatment, or up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months
Plasma Pharmacokinetics (PK): Steady State Area Under the Plasma Concentration Curve (AUC)
Up to 9 samples per participant were obtained at specific time points. Plasma concentrations of lenvatinib were analyzed using standard analysis methods. Due to the sparse PK sampling in this study, the data were pooled with data from other Phase 1 studies conducted in participants with solid tumors for PK model development and covariate analysis. Individual exposure (steady state AUC) to lenvatinib in MTC and DTC subjects in this study was derived based on the individual predicted steady state AUC from the final PK model. Only data for participants taking 24 mg lenvatinib daily were reported (participants taking 20 mg lenvatinib daily were not included in this data set).
Time frame: Cycle 1 Day 1 (predose and at 0.5 and 2 hours postdose), Cycle 1 Day 8 (predose), Cycle 2 Day 1 (predose and at 0.5 and 2 hours postdose), and Cycle 3 Day 1 (predose and at 2 hours postdose) (Cycle length= 28 days)
Change From Baseline in Free Thyroxine (T4)
Blood samples to measure free T4 were collected at Screening (Baseline), Cycle 1 Day 15 (MTC cohort), Day 1 of Cycles 2 to 20, and Final Visit. Changes in free T4 concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.
Time frame: Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 20, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Change From Baseline in Free Thyroid Stimulating Hormone (TSH)
Blood samples to measure free TSH were collected at Screening (Baseline), Cycle 1 Day 15 (MTC cohort), Day 1 of Cycles 2 to 20, and Final Visit. Changes in free TSH concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. For any free TSH result that was reported as \<0.008 mIU/L, 0.004 mIU/L was used for calculating summary statistics.
Time frame: Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 20, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Percent Change From Baseline in Concentrations of Thyroglobulin (DTC Only)
Blood samples to obtain serum were collected at Cycle 1 Day 1 (Baseline), Day 1 of Cycles 2 to 19, Final Visit, and were analyzed for thyroglobulin concentration. Percent changes in thyroglobulin concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.
Time frame: Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 19, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Percent Change From Baseline in Concentrations of Calcitonin (MTC Only)
Blood samples to obtain serum were collected at Cycle 1 Day 1(Baseline), Day 1 of Cycles 2 to 20, Final Visit, and were analyzed for calcitonin concentration. Percent changes in calcitonin concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.
Time frame: Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 20, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Percent Change From Baseline in Concentrations of Carcinoembryonic Antigen (CEA) (MTC Only)
Blood samples were collected at Cycle 1 Day 1(Baseline), Day 1 of Cycles 2 to 20, Final Visit, and were analyzed for CEA concentration. Percent changes in CEA concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.
Time frame: Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 20, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Change From Baseline in Concentrations of Cytochrome C (CytoC)
Blood samples to obtain serum were collected at Cycle 1 Day 1(Baseline), Cycle 1 Day 8, Cycle 2 Days 1,8 \&15, Cycles 3 to 9,11,13 Day 1, Final Visit, and analyzed for CytoC concentration. Changes in CytoC concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. For results reported as below quantifiable level (BQL), zero was used for calculating summary statistics. If more than 50% of the results at a visit were BQL, then only 'n', 'minimum' and 'maximum' were calculated for summary statistics.
Time frame: Cycle 1 (Day 8), Cycle 2 (Days 1, 8 and 15), Cycles 3, 4, 5, 6, 7, 8, 9, 11, & 13 (Day 1), and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Change From Baseline in Concentrations of M-30 Neo-Antigen
Blood samples to obtain serum were collected at Cycle 1 Day 1(Baseline), Cycle 1 Day 8, Cycle 2 Days 1,8 \&15, Cycles 3 to 9,11,13 Day 1, Final Visit, and analyzed for M-30 concentration. Changes in M-30 concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. For results reported as BQL, zero was used for calculating summary statistics. If more than 50% of the results at a visit were BQL, then only 'n', 'minimum' and 'maximum' were calculated for summary statistics.
Time frame: Cycle 1 (Day 8), Cycle 2 (Days 1, 8 & 15), Cycles 3, 4, 5, 6, 7, 8, 9, 11 & 13 (Day 1) and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Change From Baseline in Concentrations of Activated Caspase 3/7 (Casp 3/7)
Blood samples to obtain serum were collected at Cycle 1 Day 1 (Baseline), Cycle 1 Day 8, Cycle 2 Days 1, 8, and 15, Cycles 3 to 9, 11, 13 (Day 1), Final Visit, and analyzed for Casp 3/7 concentration. Changes in Casp 3/7 concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. The concentrations of Casp 3/7 were BQL for most participants at most time points. For results reported as BQL, zero was used for calculating summary statistics. If more than 50% of the results at a visit were BQL, then only 'n', 'minimum' and 'maximum' were calculated for summary statistics.
Time frame: Cycle 1 (Day 8), Cycle 2 (Days 1, 8, & 15), Cycles 3, 4, 5, 6, 7, 8, 9, 11, & 13 (Day 1) and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Duration of Response (DoR) Assessed as Per Independent Imaging Reviewers (IIR)
DoR was based on IIR was the time from date of the first CR or PR until the date of first documentation of disease progression or date of death, if death occurred prior to disease progression, for the participants who had BOR of CR or PR. Participants without progressive disease or death were censored at the date of last adequate tumor assessment. Duration of response = End Date - Date of first CR or PR + 1
Time frame: From date of the first CR or PR until the date of first documentation of disease progression or date of death, assessed up to data cutoff date 11 April 2011
Disease Control Rate (DCR) Assessed as Per IIR
DCR was the percentage of the participants who had BOR of CR, PR, and stable disease (SD) with the minimum duration of SD lasting greater than or equal to 7 weeks, based on assessments by IIR. DCR = CR+PR+SD greater than or equal to 7 weeks
Time frame: From date of treatment start until disease progression, development of unacceptable toxicity, withdrawal of consent, participant's choice to stop study treatment, or up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months
Clinical Benefit Rate (CBR) Assessed as Per IIR
CBR was the percentage of the participants who had BOR of CR, PR, and SD with the minimum duration of SD lasting greater than or equal to 23 weeks, based on assessments by IIR. CBR = CR+PR+SD greater than or equal to 23 weeks
Time frame: From date of treatment start until disease progression, development of unacceptable toxicity, withdrawal of consent, participant's choice to stop study treatment, or up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months
Time to Response (TTR) Assessed as Per IIR
TTR was defined as "time from start of treatment to the time when a participant first achieves a response of PR/CR" based on assessments by IIR. TTR was only calculated for participants with confirmed PR or CR.
Time frame: From date of treatment start until date of first CR or PR, assessed up to data cutoff date 11 April 2011
Progression Free Survival (PFS) Assessed as Per IIR
PFS was defined as the time from the date of treatment start until progressive disease or death from any cause in the absence of progressive disease. Disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions as assessed by IIR using RECIST 1.0. The duration of PFS was calculated as end date minus date of first drug plus 1, based on assessments by IIR. PFS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% Cl.
Time frame: From date of treatment start until date of progressive disease or death from any cause, assessed up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months
Overall Survival (OS)
OS was defined as the time from the date of treatment start until death from any cause. The duration of OS was calculated as 'end date minus date of first drug plus 1', based on assessments by IIR. Participants without a reported death or those lost to follow-up were censored at their last known alive date at the database cutoff. OS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% Cl.
Time frame: From date of treatment start until date of death from any cause, assessed up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months
Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib
Safety assessments consisted of monitoring and recording all AEs (serious and non-serious) and SAEs; concomitant medications, regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs, Eastern Cooperative Oncology Group (ECOG) performance status, New York Heart Association (NYHA) assessments, electrocardiograms (ECGs), echocardiograms; and performance of physical examinations.
Time frame: For each participant, from the first dose till 30 days after the last dose of study treatment (up to approximately 10 years 4 months)
162 participants were screened for entry into the study, from which 45 were screening failures and 117 entered into the study and were treated.
| Milestone | DTC Cohort | MTC Cohort |
|---|---|---|
| Started | 58 | 59 |
| Completed | 58 | 59 |
| Not completed | 0 | 0 |
ORR was the percentage of participants with best overall response (BOR) of complete response (CR) and partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 for target lesions using magnetic resonance imaging/computed tomography (MRI/CT) scans, as determined by independent imaging review (IIR). CR was defined as disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter. ORR=CR+PR, was presented with 2-sided 95% confidence interval (CI) by the method of Clopper and Pearson.
| Percentage of participants | DTC Cohort | MTC Cohort |
|---|---|---|
| Objective Response Rate (ORR) | 50.0 (36.6 to 63.4) | 35.6 (23.6 to 49.1) |
Up to 9 samples per participant were obtained at specific time points. Plasma concentrations of lenvatinib were analyzed using standard analysis methods. Due to the sparse PK sampling in this study, the data were pooled with data from other Phase 1 studies conducted in participants with solid tumors for PK model development and covariate analysis. Individual exposure (steady state AUC) to lenvatinib in MTC and DTC subjects in this study was derived based on the individual predicted steady state AUC from the final PK model. Only data for participants taking 24 mg lenvatinib daily were reported (participants taking 20 mg lenvatinib daily were not included in this data set).
| ng·h/mL | DTC Cohort | MTC Cohort |
|---|---|---|
| Plasma Pharmacokinetics (PK): Steady State Area Under the Plasma Concentration Curve (AUC) | 3840 (1610 to 6960) | 3350 (1040 to 6840) |
Blood samples to measure free T4 were collected at Screening (Baseline), Cycle 1 Day 15 (MTC cohort), Day 1 of Cycles 2 to 20, and Final Visit. Changes in free T4 concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.
| pmol/L | DTC Cohort | MTC Cohort |
|---|---|---|
| Cycle 1 Day 15 | — | -3.80 |
| Cycle 2 Day 1 | -0.46 ± 5.149 | -0.86 ± 3.913 |
| Cycle 3 Day 1 | -0.92 ± 4.985 | -1.00 ± 4.028 |
| Cycle 4 Day 1 | -1.05 ± 5.581 | 0.34 ± 4.192 |
| Cycle 5 Day 1 | -1.03 ± 5.563 | -0.46 ± 3.878 |
| Cycle 6 Day 1 | -2.19 ± 5.373 | -0.17 ± 4.719 |
| Cycle 7 Day 1 | -2.32 ± 5.098 | -1.07 ± 5.403 |
| Cycle 8 Day 1 | -1.74 ± 5.504 | -1.13 ± 5.691 |
| Cycle 9 Day 1 | -0.39 ± 5.295 | 0.52 ± 5.213 |
| Cycle 10 Day 1 | -0.26 ± 6.397 | 1.33 ± 6.319 |
| Cycle 11 Day 1 | -0.27 ± 6.384 | 0.30 ± 5.551 |
| Cycle 12 Day 1 | -1.60 ± 6.331 | -0.43 ± 5.380 |
| Cycle 13 Day 1 | -0.09 ± 5.416 | 0.07 ± 4.347 |
| Cycle 14 Day 1 | -0.54 ± 5.772 | -0.82 ± 6.394 |
| Cycle 15 Day 1 | 0.63 ± 6.703 | -1.01 ± 5.505 |
| Cycle 16 Day 1 | -0.98 ± 7.150 | 0.60 ± 4.142 |
| Cycle 17 Day 1 | 1.20 ± 7.075 | 0.45 ± 3.528 |
| Cycle 18 Day 1 | 0.38 ± 4.648 | 2.17 ± 4.831 |
| Cycle 19 Day 1 | -0.65 ± 4.042 | 3.25 ± 4.596 |
| Cycle 20 Day 1 | — | 5.20 |
| Final Visit/Study Termination | -0.36 ± 6.175 | 1.27 ± 4.584 |
Blood samples to measure free TSH were collected at Screening (Baseline), Cycle 1 Day 15 (MTC cohort), Day 1 of Cycles 2 to 20, and Final Visit. Changes in free TSH concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. For any free TSH result that was reported as \<0.008 mIU/L, 0.004 mIU/L was used for calculating summary statistics.
| mIU/L | DTC Cohort | MTC Cohort |
|---|---|---|
| Cycle 1 Day 15 | — | 2.8030 |
| Cycle 2 Day 1 | 0.4779 ± 3.07666 | 4.1585 ± 7.34946 |
| Cycle 3 Day 1 | 0.5161 ± 2.79122 | 5.5788 ± 13.76600 |
| Cycle 4 Day 1 | 0.6296 ± 2.29420 | 2.8751 ± 6.50098 |
| Cycle 5 Day 1 | 0.5024 ± 2.22721 | 3.7098 ± 6.60386 |
| Cycle 6 Day 1 | 0.8603 ± 3.09079 | 3.9822 ± 10.65477 |
| Cycle 7 Day 1 | 0.6660 ± 2.08608 | 8.4308 ± 22.51715 |
| Cycle 8 Day 1 | 0.2118 ± 3.16324 | 11.4131 ± 32.65896 |
| Cycle 9 Day 1 | 0.1270 ± 3.53020 | 6.6620 ± 18.89412 |
| Cycle 10 Day 1 | -0.3277 ± 2.87114 | 6.1934 ± 17.99762 |
| Cycle 11 Day 1 | -0.2940 ± 3.28192 | 2.7928 ± 9.42343 |
| Cycle 12 Day 1 | 0.3500 ± 5.43946 | 5.1879 ± 14.81415 |
| Cycle 13 Day 1 | -0.2799 ± 3.31518 | 2.0983 ± 7.03903 |
| Cycle 14 Day 1 | -0.6232 ± 3.09954 | 9.6490 ± 32.48910 |
| Cycle 15 Day 1 | -0.5911 ± 3.21447 | 0.9955 ± 4.93549 |
| Cycle 16 Day 1 | -0.3396 ± 3.68903 | 0.2971 ± 3.33103 |
| Cycle 17 Day 1 | -1.0352 ± 3.92286 | 7.4624 ± 16.18545 |
| Cycle 18 Day 1 | 0.0331 ± 0.24520 | 4.1232 ± 7.01461 |
| Cycle 19 Day 1 | 0.7805 ± 1.87674 | -0.2080 ± 0.29698 |
| Cycle 20 Day 1 | — | 0.0000 |
| Final Visit/Study Termination | 1.0281 ± 2.07161 | 3.4905 ± 7.39625 |
Blood samples to obtain serum were collected at Cycle 1 Day 1 (Baseline), Day 1 of Cycles 2 to 19, Final Visit, and were analyzed for thyroglobulin concentration. Percent changes in thyroglobulin concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.
| percent change | DTC Cohort |
|---|---|
| Cycle 2 Day 1 | -62.21 ± 39.997 |
| Cycle 3 Day 1 | -77.80 ± 22.278 |
| Cycle 4 Day 1 | -79.25 ± 26.639 |
| Cycle 5 Day 1 | -76.00 ± 25.085 |
| Cycle 6 Day 1 | -20.36 ± 373.190 |
| Cycle 7 Day 1 | -73.38 ± 45.489 |
| Cycle 8 Day 1 | -79.96 ± 27.461 |
| Cycle 9 Day 1 | -73.98 ± 31.366 |
| Cycle 10 Day 1 | -78.26 ± 25.524 |
| Cycle 11 Day 1 | -75.54 ± 37.327 |
| Cycle 12 Day 1 | -73.51 ± 46.397 |
| Cycle 13 Day 1 | -74.05 ± 37.091 |
| Cycle 14 Day 1 | -78.70 ± 17.348 |
| Cycle 15 Day 1 | -80.28 ± 16.029 |
| Cycle 16 Day 1 | -76.38 ± 27.736 |
| Cycle 17 Day 1 | -62.99 ± 38.740 |
| Cycle 18 Day 1 | -72.67 ± 27.226 |
| Cycle 19 Day 1 | -50.65 ± 46.900 |
| Final Visit/Study Termination | -68.60 |
Blood samples to obtain serum were collected at Cycle 1 Day 1(Baseline), Day 1 of Cycles 2 to 20, Final Visit, and were analyzed for calcitonin concentration. Percent changes in calcitonin concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.
| percent change | MTC Cohort |
|---|---|
| Cycle 2 Day 1 | -42.27 ± 38.754 |
| Cycle 3 Day 1 | -48.11 ± 30.976 |
| Cycle 4 Day 1 | -44.54 ± 38.794 |
| Cycle 5 Day 1 | -49.97 ± 34.634 |
| Cycle 6 Day 1 | -41.73 ± 46.653 |
| Cycle 7 Day 1 | -38.18 ± 62.721 |
| Cycle 8 Day 1 | -47.29 ± 46.101 |
| Cycle 9 Day 1 | -37.52 ± 72.588 |
| Cycle 10 Day 1 | -39.57 ± 60.118 |
| Cycle 11 Day 1 | -42.68 ± 61.797 |
| Cycle 12 Day 1 | -29.25 ± 105.440 |
| Cycle 13 Day 1 | -36.26 ± 89.612 |
| Cycle 14 Day 1 | -18.16 ± 148.928 |
| Cycle 15 Day 1 | -65.26 ± 24.553 |
| Cycle 16 Day 1 | -64.24 ± 30.394 |
| Cycle 17 Day 1 | -66.03 ± 23.777 |
| Cycle 18 Day 1 | -64.57 ± 27.982 |
| Cycle 19 Day 1 | -44.30 ± 18.668 |
| Cycle 20 Day 1 | -29.40 |
| Final Visit/Study Termination | -36.70 ± 28.296 |
Blood samples were collected at Cycle 1 Day 1(Baseline), Day 1 of Cycles 2 to 20, Final Visit, and were analyzed for CEA concentration. Percent changes in CEA concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.
| percent change | MTC Cohort |
|---|---|
| Cycle 2 Day 1 | -26.07 ± 45.864 |
| Cycle 3 Day 1 | -37.68 ± 42.236 |
| Cycle 4 Day 1 | -41.49 ± 48.035 |
| Cycle 5 Day 1 | -44.62 ± 42.138 |
| Cycle 6 Day 1 | -41.91 ± 47.388 |
| Cycle 7 Day 1 | -41.39 ± 45.677 |
| Cycle 8 Day 1 | -42.89 ± 47.818 |
| Cycle 9 Day 1 | -49.31 ± 32.185 |
| Cycle 10 Day 1 | -47.35 ± 31.621 |
| Cycle 11 Day 1 | -51.75 ± 29.671 |
| Cycle 12 Day 1 | -49.91 ± 32.597 |
| Cycle 13 Day 1 | -46.44 ± 35.967 |
| Cycle 14 Day 1 | -47.98 ± 38.324 |
| Cycle 15 Day 1 | -56.62 ± 34.051 |
| Cycle 16 Day 1 | -59.83 ± 34.762 |
| Cycle 17 Day 1 | -53.80 ± 37.981 |
| Cycle 18 Day 1 | -46.00 ± 39.905 |
| Cycle 19 Day 1 | -45.65 ± 18.738 |
| Cycle 20 Day 1 | -61.40 |
| Final Visit/Study Termination | -29.43 ± 31.453 |
Blood samples to obtain serum were collected at Cycle 1 Day 1(Baseline), Cycle 1 Day 8, Cycle 2 Days 1,8 \&15, Cycles 3 to 9,11,13 Day 1, Final Visit, and analyzed for CytoC concentration. Changes in CytoC concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. For results reported as below quantifiable level (BQL), zero was used for calculating summary statistics. If more than 50% of the results at a visit were BQL, then only 'n', 'minimum' and 'maximum' were calculated for summary statistics.
| pg/mL | DTC Cohort | MTC Cohort |
|---|---|---|
| Cycle 1 Day 8 | 155.57 ± 825.091 | 502.84 ± 2146.291 |
| Cycle 2 Day 1 | — | 1679.40 |
| Cycle 2 Day 8 | -218.45 ± 591.217 | 374.46 ± 2279.207 |
| Cycle 2 Day 15 | -215.50 | — |
| Cycle 3 Day 1 | -175.43 ± 435.635 | 311.85 ± 2363.970 |
| Cycle 4 Day 1 | 1.38 ± 268.354 | 63.01 ± 1738.149 |
| Cycle 5 Day 1 | -21.32 ± 85.469 | 1078.85 ± 3793.235 |
| Cycle 6 Day 1 | 721.58 ± 1234.215 | 1411.29 ± 3855.502 |
| Cycle 7 Day 1 | 858.05 ± 1383.962 | 2184.30 ± 4689.181 |
| Cycle 8 Day 1 | 1358.51 ± 1364.706 | 451.36 ± 254.305 |
| Cycle 9 Day 1 | 1356.40 ± 913.685 | 459.38 ± 1572.717 |
| Cycle 11 Day 1 | 139.60 | — |
| Cycle 13 Day 1 | 129.60 | — |
| Final Visit/Study Termination | 249.31 ± 765.148 | -45.97 ± 1294.476 |
Blood samples to obtain serum were collected at Cycle 1 Day 1(Baseline), Cycle 1 Day 8, Cycle 2 Days 1,8 \&15, Cycles 3 to 9,11,13 Day 1, Final Visit, and analyzed for M-30 concentration. Changes in M-30 concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. For results reported as BQL, zero was used for calculating summary statistics. If more than 50% of the results at a visit were BQL, then only 'n', 'minimum' and 'maximum' were calculated for summary statistics.
| U/L | DTC Cohort | MTC Cohort |
|---|---|---|
| Cycle 1 Day 8 | -5.22 ± 108.639 | 46.32 ± 197.509 |
| Cycle 2 Day 1 | — | -77.80 |
| Cycle 2 Day 8 | -26.41 ± 257.723 | -49.33 ± 289.525 |
| Cycle 2 Day 15 | 35.30 | — |
| Cycle 3 Day 1 | 19.70 ± 296.010 | -90.21 ± 314.343 |
| Cycle 4 Day 1 | -7.89 ± 336.124 | -97.53 ± 296.832 |
| Cycle 5 Day 1 | -24.83 ± 397.337 | -161.36 ± 265.548 |
| Cycle 6 Day 1 | -99.30 ± 321.554 | -161.30 ± 214.299 |
| Cycle 7 Day 1 | -168.50 ± 378.071 | -52.79 ± 129.671 |
| Cycle 8 Day 1 | -180.22 ± 386.682 | -92.44 ± 57.828 |
| Cycle 9 Day 1 | -111.92 ± 189.411 | -85.22 ± 161.751 |
| Cycle 11 Day 1 | 55.00 | — |
| Cycle 13 Day 1 | -263.50 | — |
| Final Visit/Study Termination | -151.73 ± 322.159 | -158.99 ± 355.903 |
Blood samples to obtain serum were collected at Cycle 1 Day 1 (Baseline), Cycle 1 Day 8, Cycle 2 Days 1, 8, and 15, Cycles 3 to 9, 11, 13 (Day 1), Final Visit, and analyzed for Casp 3/7 concentration. Changes in Casp 3/7 concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. The concentrations of Casp 3/7 were BQL for most participants at most time points. For results reported as BQL, zero was used for calculating summary statistics. If more than 50% of the results at a visit were BQL, then only 'n', 'minimum' and 'maximum' were calculated for summary statistics.
| U/W | DTC Cohort | MTC Cohort |
|---|---|---|
| Cycle 1 Day 8 | NA ± NA | 0.0030 ± 0.00610 |
| Cycle 2 Day 1 | — | 0.0080 |
| Cycle 2 Day 8 | NA ± NA | 0.0039 ± 0.00822 |
| Cycle 2 Day 15 | 0.0110 | — |
| Cycle 3 Day 1 | NA ± NA | 0.0026 ± 0.00691 |
| Cycle 4 Day 1 | NA ± NA | 0.0019 ± 0.00743 |
| Cycle 5 Day 1 | NA ± NA | 0.0042 ± 0.00666 |
| Cycle 6 Day 1 | 0.0046 ± 0.00605 | NA ± NA |
| Cycle 7 Day 1 | 0.0058 ± 0.00496 | 0.0044 ± 0.00692 |
| Cycle 8 Day 1 | 0.0078 ± 0.00771 | NA ± NA |
| Cycle 9 Day 1 | 0.0067 ± 0.00480 | 0.0068 ± 0.01329 |
| Cycle 11 Day 1 | NA ± NA | — |
| Cycle 13 Day 1 | NA ± NA | — |
| Final Visit/Study Termination | NA ± NA | NA ± NA |
DoR was based on IIR was the time from date of the first CR or PR until the date of first documentation of disease progression or date of death, if death occurred prior to disease progression, for the participants who had BOR of CR or PR. Participants without progressive disease or death were censored at the date of last adequate tumor assessment. Duration of response = End Date - Date of first CR or PR + 1
| Months | DTC Cohort | MTC Cohort |
|---|---|---|
| Duration of Response (DoR) Assessed as Per Independent Imaging Reviewers (IIR) | 12.7 (8.8 to NA) | NA (5.7 to NA) |
DCR was the percentage of the participants who had BOR of CR, PR, and stable disease (SD) with the minimum duration of SD lasting greater than or equal to 7 weeks, based on assessments by IIR. DCR = CR+PR+SD greater than or equal to 7 weeks
| Percentage of participants | DTC Cohort | MTC Cohort |
|---|---|---|
| Disease Control Rate (DCR) Assessed as Per IIR | 93.1 (83.3 to 98.1) | 79.7 (67.2 to 89.0) |
CBR was the percentage of the participants who had BOR of CR, PR, and SD with the minimum duration of SD lasting greater than or equal to 23 weeks, based on assessments by IIR. CBR = CR+PR+SD greater than or equal to 23 weeks
| Percentage of participants | DTC Cohort | MTC Cohort |
|---|---|---|
| Clinical Benefit Rate (CBR) Assessed as Per IIR | 77.6 (64.7 to 87.5) | 64.4 (50.9 to 76.4) |
TTR was defined as "time from start of treatment to the time when a participant first achieves a response of PR/CR" based on assessments by IIR. TTR was only calculated for participants with confirmed PR or CR.
| Months | DTC Cohort | MTC Cohort |
|---|---|---|
| Time to Response (TTR) Assessed as Per IIR | 3.6 (1.8 to 3.7) | 3.5 (1.9 to 3.7) |
PFS was defined as the time from the date of treatment start until progressive disease or death from any cause in the absence of progressive disease. Disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions as assessed by IIR using RECIST 1.0. The duration of PFS was calculated as end date minus date of first drug plus 1, based on assessments by IIR. PFS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% Cl.
| Months | DTC Cohort | MTC Cohort |
|---|---|---|
| Progression Free Survival (PFS) Assessed as Per IIR | 12.6 (9.9 to 16.1) | 9.0 (7.0 to NA) |
OS was defined as the time from the date of treatment start until death from any cause. The duration of OS was calculated as 'end date minus date of first drug plus 1', based on assessments by IIR. Participants without a reported death or those lost to follow-up were censored at their last known alive date at the database cutoff. OS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% Cl.
| Months | DTC Cohort | MTC Cohort |
|---|---|---|
| Overall Survival (OS) | 27.7 (27.7 to NA) | 16.6 (16.4 to NA) |
Safety assessments consisted of monitoring and recording all AEs (serious and non-serious) and SAEs; concomitant medications, regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs, Eastern Cooperative Oncology Group (ECOG) performance status, New York Heart Association (NYHA) assessments, electrocardiograms (ECGs), echocardiograms; and performance of physical examinations.
| Participants | DTC Cohort | MTC Cohort |
|---|---|---|
| Non-Serious AEs | 58 | 59 |
| SAEs | 32 | 42 |
Collected over For each participant, from the first dose till 30 days after the last dose of study treatment (up to approximately 10 years 4 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DTC Cohort | 44/58 (75.9%) | 32/58 (55.2%) | 58/58 (100%) |
| MTC Cohort | 37/59 (62.7%) | 42/59 (71.2%) | 59/59 (100%) |
| Event | DTC Cohort | MTC Cohort |
|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/58 | 3/59 |
| DehydrationMetabolism and nutrition disorders | 4/58 | 3/59 |
| HypotensionVascular disorders | 4/58 | 1/59 |
| PneumoniaInfections and infestations | 2/58 | 4/59 |
| Abdominal painGastrointestinal disorders | 0/58 | 3/59 |
| Decreased appetiteMetabolism and nutrition disorders | 1/58 | 3/59 |
| Lung infectionInfections and infestations | 0/58 | 3/59 |
| AmenorrhoeaReproductive system and breast disorders | 0/58 | 3/59 |
| Abdominal pain lowerGastrointestinal disorders | 2/58 | 0/59 |
| HypertensionVascular disorders | 2/58 | 1/59 |
| Event | DTC Cohort | MTC Cohort |
|---|---|---|
| HypertensionVascular disorders | 45/58 | 31/59 |
| DiarrhoeaGastrointestinal disorders | 40/58 | 45/59 |
| ProteinuriaRenal and urinary disorders | 41/58 | 38/59 |
| Weight decreasedInvestigations | 39/58 | 29/59 |
| FatigueGeneral disorders | 35/58 | 33/59 |
| Decreased appetiteMetabolism and nutrition disorders | 32/58 | 32/59 |
| NauseaGastrointestinal disorders | 30/58 | 30/59 |
| CoughRespiratory, thoracic and mediastinal disorders | 28/58 | 24/59 |
| HeadacheNervous system disorders | 27/58 | 27/59 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 25/58 | 20/59 |
Intent-to-treat population included all participants who received at least one dose of the study drug and was the primary analysis set for efficacy analyses.
| Age, Continuous(Years) | DTC Cohort | MTC Cohort | Total |
|---|---|---|---|
| Mean | 60.9 ± 9.49 | 51.6 ± 14.11 | 56.2 ± 12.88 |
| Sex: Female, Male(Participants) | DTC Cohort | MTC Cohort | Total |
|---|---|---|---|
| Female | 24 | 22 | 46 |
| Male | 34 | 37 | 71 |
Ran from Nov 2008 to primary completion in Apr 2011, 29 months.
Results were first posted in Aug 2019, 8 years 3 months after primary completion.
Of 92 phase 2 interventional studies under Thyroid Neoplasms, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 119. This study's 29 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib